Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

ANIX
Anixa Biosciences, Inc.
stock NASDAQ

Market Open
Jul 30, 2026 10:26:34 AM EDT
3.43USD-0.291%(-0.01)34,977
3.39Bid   3.92Ask   0.53Spread
Pre-market
Jul 30, 2026 9:09:30 AM EDT
3.49USD+1.363%(+0.05)499
After-hours
Jul 28, 2026 4:53:30 PM EDT
3.57USD+1.548%(+0.05)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 25, 2022
08:47AM EST  Anixa Biosciences Reports Japanese Patent On Ovarian Cancer Vaccine   RTTNews
08:35AM EST  Anixa Biosciences Announces Japanese Patent On Ovarian Cancer Vaccine   Benzinga
Jan 24, 2022
08:33AM EST  Anixa Biosciences And MolGenie Announce Early Potency Analysis Of SARS-CoV-2 Protease Inhibitor   Benzinga
08:31AM EST  Anixa Biosciences and MolGenie Announce Early Potency Analysis of SARS-CoV-2   PR Newswire
Dec 16, 2021
08:31AM EST  LifeSci Partners Annual Corporate Access Event and H.C. Wainwright BioConnect Conference   PR Newswire
Dec 7, 2021
09:25AM EST  Benzinga Pro's Top 5 Stocks To Watch For Tuesday, Dec. 7, 2021: INTC, MTOR, ANIX, LMDX, ITI   Benzinga
09:24AM EST  Anixa Biosciences Inc. (ANIX) and MolGenie said that their COVID-19 compounds are expected to be effective against the Omicron Variant as well as the Delta variant.   RTTNews
08:39AM EST  Anixa Biosciences, MolGenie COVID-19 Compounds Expected To Be Effective Against Omicron Variant   RTTNews
08:32AM EST  Anixa Biosciences, MolGenie Report Their COVID-19 Compounds Expected To Be Effective Against Omicron Variant   Benzinga
08:31AM EST  Anixa Biosciences and MolGenie Announce that their COVID-19 Compounds are   PR Newswire
Nov 2, 2021
01:09PM EDT  Anixa Biosciences US Patent & Trademark Office Abstract For Co.'s 'Methods for using artificial neural network analysis on flow cytometry data for cancer diagnosis'   Benzinga
Oct 26, 2021
08:51AM EDT  Anixa Biosciences Announces Patient Dosing Of Its Investigational Vaccine Candidate In A First-Of-Its-Kind Preventative Breast Cancer Vaccine Study   Benzinga
08:37AM EDT  Anixa Announces Patient Dosing Of Its Vaccine Candidate In First-of-its-Kind Preventative Breast Cancer Vaccine Study   RTTNews
08:35AM EDT  Anixa Biosciences Announces Patient Dosing of its Investigational Vaccine   PR Newswire
Oct 6, 2021
08:34AM EDT  Anixa Biosciences Announces First Chinese Patent On CAR-T Cancer Therapy Technology   Benzinga
08:32AM EDT  Anixa Biosciences Reports First Chinese Patent On Its CAR-T Cancer Therapy Technology   RTTNews
08:31AM EDT  Anixa Biosciences Announces First Chinese Patent on its CAR-T Cancer Therapy   PR Newswire
Oct 1, 2021
08:32AM EDT  Anixa Announces Notice Of Allowance For Additional Patent On CAR-T Cancer Therapy   RTTNews
08:31AM EDT  Anixa Biosciences Announces Notice Of Allowance For Additional Patent On Its CAR-T Cancer Therapy   Benzinga
08:31AM EDT  Anixa Biosciences Announces Notice of Allowance for Additional Patent on its   PR Newswire
Sep 14, 2021
08:32AM EDT  Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Discussed at Upcoming   PR Newswire
Sep 8, 2021
08:31AM EDT  Anixa Biosciences to Present at the H.C. Wainwright 23rd Annual Global   PR Newswire
Sep 7, 2021
08:32AM EDT  Anixa Biosciences Appoints Dr. Pamela Garzone As Chief Development Officer   PR Newswire
Aug 30, 2021
08:55AM EDT  Biotechnology company Anixa Biosciences, Inc. (ANIX) announced Monday that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for its CAR-T (Chimeric Antigen Receptor-T cell) therapy, which is being developed in partnership with Moffitt Cancer Center.   RTTNews
08:34AM EDT  Anixa And Moffitt Cancer Center Announce FDA Clearance To Initiate Clinical Trial Of Ovarian Cancer CAR-T Immunotherapy   RTTNews
08:31AM EDT  Anixa Biosciences and Moffitt Cancer Center Announce FDA Clearance to Initiate   PR Newswire
08:31AM EDT  Anixa Biosciences And Moffitt Cancer Center Announce FDA Clearance To Initiate Clinical Trial Of Ovarian Cancer CAR-T Immunotherapy   Benzinga
Aug 25, 2021
08:53AM EDT  Anixa Biosciences, Inc. (ANIX) said a genomic variant analysis indicates that the company's potential compounds may be even more effective against the Delta variant than the original wild type SARS-CoV-2. The company's program in collaboration with MolGenie, focuses on identifying small molecule inhibitors of Mpro, the main protease of the virus.   RTTNews
08:38AM EDT  Anixa Biosciences' Covid-19 Compounds Expected To Be Effective Against Delta Variant; Stock Up   RTTNews
08:31AM EDT  Anixa Biosciences Says A Genomic Variant Analysis Indicates That Its Potential Compounds 'may be even more effective against the Delta variant than the original wild type SARS-CoV-2.'   Benzinga
08:31AM EDT  Anixa Biosciences' Covid-19 Compounds Expected to be Effective Against the   PR Newswire
Aug 23, 2021
08:31AM EDT  Anixa Biosciences Congratulates Director, Dr. Arnold Baskies for His   PR Newswire
Aug 18, 2021
08:32AM EDT  Anixa Biosciences Announces Issuance Of U.S. Patent For Ovarian Cancer Vaccine Technology   RTTNews
08:31AM EDT  Anixa Biosciences Announces Issuance of U.S. Patent for Ovarian Cancer Vaccine   PR Newswire
08:31AM EDT  Anixa Biosciences Announces Issuance Of US Patent For Ovarian Cancer Vaccine Technology   Benzinga
Jul 28, 2021
10:47AM EDT  3 Penny Stocks Insiders Are Buying   Benzinga
May 26, 2021
08:32AM EDT  Anixa Biosciences Announces Its Ovarian Cancer Vaccine Technology Is Part Of An Award From National Cancer Institute Through NCI-PREVENT Program   Benzinga
08:30AM EDT  Anixa Biosciences Announces Support from the National Cancer Institute for   PR Newswire
May 20, 2021
09:56AM EDT  Anixa Biosciences Inc. (ANIX) said Thursday that the U.S. Food and Drug Administration has provided details of the additional information it is requesting regarding its Chimeric Antigen Receptor-T cell therapy or CAR-T being developed in partnership with Moffitt Cancer Center.   RTTNews
09:38AM EDT  Anixa Biosciences And Moffitt Cancer Center Receive Addl Information Request From FDA For CAR-T IND Application   RTTNews
08:37AM EDT  Anixa Biosciences And Moffitt Cancer Center Receive Additional Information Request From US FDA For CAR-T IND Application   Benzinga
08:31AM EDT  Anixa Biosciences and Moffitt Cancer Center Receive Additional Information   PR Newswire
May 7, 2021
08:36AM EDT  Anixa Biosciences Collaboration Partner OntoChem Says Has Assigned Its Drug Discovery Technologies And Assets To MolGenie GmbH   Benzinga
08:31AM EDT  OntoChem Assigns Anixa Covid-19 Drug Discovery Project to MolGenie   PR Newswire
Apr 23, 2021
03:05PM EDT  Anixa's Stock Craters As FDA Slaps Clinical Hold On CAR-T Program   Benzinga
Apr 19, 2021
02:31PM EDT  Mid-Afternoon Market Update: Nasdaq Tumbles 150 Points; Knoll Shares Spike Higher   Benzinga
12:59PM EDT  Anixa's Stock Craters As FDA Slaps Clinical Hold On CAR-T Program   Benzinga
12:20PM EDT  Mid-Day Market Update: Marlin Business Services Rises Following Acquisition News; Anixa Biosciences Shares Plummet   Benzinga
10:27AM EDT  Mid-Morning Market Update: Markets Open Lower; Coca-Cola Tops Q1 Views   Benzinga
09:48AM EDT  Anixa Biosciences Inc. (ANIX) said Monday that the U.S. Food and Drug Administration has requested additional information regarding its Chimeric Antigen Receptor-T cell therapy or CAR-T being developed in partnership with Moffitt Cancer Center or MCC.   RTTNews
08:39AM EDT  Anixa Biosciences, Moffitt Cancer Center Report FDA Request Of Additional Information For CAR-T Therapy   RTTNews
08:34AM EDT  Anixa Biosciences And Moffitt Cancer Center Report US FDA Request Of Additional Information For CAR-T Therapy; Says Study Placed On hClinical Hold Pending Submission Of Additional Information   Benzinga
08:31AM EDT  Anixa Biosciences and Moffitt Cancer Center Report US FDA Request of Additional   PR Newswire
Apr 15, 2021
10:20AM EDT  Mid-Morning Market Update: Markets Open Higher; Bank of America Beats Q1 Estimates   Benzinga
Apr 12, 2021
10:06AM EDT  Anixa Biosciences shares were trading higher after HC Wainwright & Co. initiated coverage on the stock with a Buy rating and a price target of $11 per share.   Benzinga
10:04AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For April 12, 2021   Benzinga
06:32AM EDT  HC Wainwright & Co. Initiates Coverage On Anixa Biosciences with Buy Rating, Announces Price Target of $11   Benzinga
Apr 5, 2021
08:34AM EDT  Anixa Biosciences Says Based On Proof Of Concept Animal Study Results, It Will Progress To Next Stage Of Development For Its COVID-10 Antiviral Therapy   Benzinga
08:31AM EDT  Anixa Biosciences and OntoChem Enter Next Stage of Development for Covid-19   PR Newswire
Mar 23, 2021
02:41PM EDT  Mid-Afternoon Market Update: Dow Falls Over 100 Points; Pacific Mercantile Bancorp Shares Surge   Benzinga
12:05PM EDT  Mid-Day Market Update: Crude Oil Down 4.5%; Hoth Therapeutics Shares Spike Higher   Benzinga
10:19AM EDT  Mid-Morning Market Update: Markets Edge Higher; IHS Markit Profit Beats Views   Benzinga
08:18AM EDT  The Daily Biotech Pulse: FDA Approvals For Merck, Pacira And Zealand, Roche-Regeneron Ace Late-Stage COVID-19 Study, AlloVir Appoints Gilead Virology Chief As CEO   Benzinga
Mar 22, 2021
10:00PM EDT  Anixa Biosciences Increases Previously Announced Bought Deal Offering of Common   PR Newswire
05:20PM EDT  Anixa Biosciences Prices ~1.9M Share Common Stock Offering At $5.25/Share   Benzinga
05:19PM EDT  Anixa Biosciences Announces $10 Million Bought Deal Offering of Common Stock   PR Newswire
08:36AM EDT  Anixa Biosciences And Moffitt Cancer Center File IND Application For Ovarian Cancer CAR-T Therapy   Benzinga
08:35AM EDT  Anixa Biosciences, Moffitt Cancer Center File IND Application For Ovarian Cancer CAR-T Therapy   RTTNews
08:31AM EDT  Anixa Biosciences and Moffitt Cancer Center File IND Application for Ovarian   PR Newswire
Mar 19, 2021
07:46AM EDT  The Daily Biotech Pulse: Sarepta Gene Therapy Data, Idera Plunges On Failed Skin Cancer Study, 3 IPOs   Benzinga
Mar 18, 2021
08:16AM EDT  The Daily Biotech Pulse: Translate Bio's Cystic Fibrosis Study Disappoints, Adverum Nominates Directors, Gain Therapeutics To Debut On Nasdaq   Benzinga
01:25AM EDT  Today's Daily Dose brings you news about Cannabics' drug candidate RCC-33 prolonging survival rate in mice inoculated with human colorectal cancer cells, encouraging data of Immatics' ACTengine program, and disappointing results from Translate Bio's cystic fibrosis trial.   RTTNews
Mar 12, 2021
08:35AM EST  Anixa Biosciences Highlights Publication Of European Patent For Its Ovarian Cancer Vaccine Technology   Benzinga
08:32AM EST  Anixa Announces Issuance And Publication Of European Patent For Ovarian Cancer Vaccine Technology   RTTNews
08:31AM EST  Anixa Biosciences Highlights Publication Of European Paten For Its Ovarian Cancer Vaccine Technology   Benzinga
08:30AM EST  Anixa Biosciences Announces Issuance and Publication of European Patent for   PR Newswire
Mar 8, 2021
08:47AM EST  Anixa Biosciences to Participate in M Vest LLC and Maxim Group LLC Inaugural   PR Newswire
Mar 4, 2021
08:41AM EST  Anixa Biosciences Says European Patent Issued For Its CAR-T Cancer Therapy   RTTNews
08:33AM EST  Anixa Biosciences Reports European Patent Issued For Its CAR-T Cancer Therapy   Benzinga
08:31AM EST  Anixa Biosciences Announces European Patent Issued for its CAR-T Cancer Therapy   PR Newswire
Feb 25, 2021
08:31AM EST  Anixa Biosciences to Present at the H.C. Wainwright Global Life Sciences   PR Newswire
Feb 16, 2021
08:40AM EST  Anixa Biosciences Says Begins Animal Testing Of Covid-19 Therapeutic Candidates   RTTNews
08:32AM EST  Anixa Biosciences Begins Animal Testing Of COVID-19 Therapeutic Candidates   Benzinga
Feb 9, 2021
08:10AM EST  The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement   Benzinga
Jan 13, 2021
08:31AM EST  Anixa Biosciences to Present at the B. Riley Oncology Investor Conference   PR Newswire
Jan 5, 2021
08:31AM EST  Anixa Biosciences to Present at the H.C. Wainwright BioConnect 2021 Conference   PR Newswire
Dec 21, 2020
08:42AM EST  Anixa Biosciences And Cleveland Clinic Announce FDA Clearance To Begin Clinical Trial Of Breast Cancer Vaccine   RTTNews
08:32AM EST  Anixa Biosciecnes, Cleveland Clinic Announce FDA Clearance To Initiate Clinical Trial Of Breast Cancer Vaccine   Benzinga
08:31AM EST  Anixa Biosciences and Cleveland Clinic Announce FDA Clearance to Initiate   PR Newswire
Dec 14, 2020
09:02AM EST  Anixa Biosciences And Partner OntoChem Announce Their GmbH Covid-19 Therapy 'Demonstrates Comparable Potency to Remdesivir in Pre-Clinical Testing'   Benzinga
09:01AM EST  Anixa Biosciences Covid-19 Therapy Demonstrates Comparable Potency to   PR Newswire
Dec 11, 2020
08:11AM EST  The Daily Biotech Pulse: Pfizer-BioNTech Receive FDA Panel Backing, Sanofi-GSK Disclose Delay In Vaccine Program, 4 Biotechs To Debut On Wall Street   Benzinga
Dec 1, 2020
09:06AM EST  Anixa Biosciences Announces Licensing Agreement With Cleveland Clinic For Ovarian Cancer Vaccine Technology   Benzinga
09:06AM EST  Anixa Biosciences Announces Licensing Agreement with Cleveland Clinic for   PR Newswire
Nov 25, 2020
08:26AM EST  Benzinga Pro's Top 5 Stocks To Watch For Wednesday Nov. 25: WIMI, RKDA, ANIX, JKS, NIO   Benzinga
Nov 23, 2020
08:33AM EST  Anixa Biosciences Says An IND Application For Prophylactic Breast Cancer Vaccine Filed With FDA   RTTNews
08:31AM EST  Anixa Biosciences, Cleveland Clinic File IND Application For Breast Cancer Vaccine   Benzinga
08:31AM EST  Anixa Biosciences and Cleveland Clinic File IND Application for Breast Cancer   PR Newswire
Oct 27, 2020
08:02AM EDT  Anixa Biosciences to Host Conference Call to Provide Update on Programs   PR Newswire
Sep 14, 2020
11:43AM EDT  Insider Buys Anixa Biosciences Shares   Benzinga
Sep 8, 2020
08:01AM EDT  Anixa Biosciences to Present at the 2020 H.C. Wainwright 22nd Annual Global   PR Newswire
Aug 13, 2020
09:04AM EDT  Anixa Biosciences, Co. Partner, OntoChem, Report Have Identified Added Candidates Through In Silico Screening Study   Benzinga
09:02AM EDT  Anixa and OntoChem Announce Identification of Additional Covid-19 Compounds   PR Newswire
Jul 28, 2020
09:10AM EDT  Anixa Biosciences Breast Cancer Vaccine Technology Nearing FDA Submission   Benzinga
Jul 20, 2020
09:01AM EDT  Anixa Biosciences Announces Change to Virtual Format for 2020 Annual Meeting of   PR Newswire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC